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Background: When designing therapeutic short-interfering RNAs (siRNAs), off-target effects (OTEs) are usually predicted by
computational quantification of messenger RNAs (mRNAs) that contain matches to the siRNA seed sequence in their 30 UTRs. It is
assumed that the higher the number of predicted transcriptional OTEs, the greater the size of the actual OTE signature and the
more detrimental the phenotypic consequences in target-negative cells.
Methods: We tested this general assumption by investigating the OTEs of potential therapeutic siRNAs targeting the human
papillomavirus (HPV) type-16 E7 oncogene. We studied HPV-negative squamous epithelial cells, from normal cervix (NCx) and skin
(HaCaT), which would be vulnerable to ‘bystander’ OTEs following transfection in vivo.
Results: We observed no correlation between the number of computationally predicted OTEs and the actual number of seed-
dependent OTEs (P¼ 0.76). On average only 20.5% of actual transcriptional OTEs were seed-dependent (i.e., predicted). The
unpredicted OTEs included stimulation of innate immune pathways, as well as indirect (downstream) effects of other OTEs, which
affected important cancer-associated pathways. Although most significant OTEs observed were seen in both NCx and HaCaT
cells, only 0–5.9% of differentially expressed genes overlapped between the two cell types.
Conclusion: These data do not support the assumption that actual OTEs correlate well with predicted OTEs.
RNA interference (RNAi) is an endogenous process that causes
sequence-specific downregulation of target messenger (mRNA)
molecules. It is mediated by short, non-coding RNAs, particularly
microRNAs (miRNAs) and short-interfering RNAs (siRNAs).
Individual miRNAs generally have numerous mRNA targets
(Lim et al, 2005), determined via their ‘seed-region’ (predomi-
nantly nucleotides at 50 positions 2–7; 2–7 nt (Lewis et al, 2005)),
which binds to a seed-complementary region (SCR) in target
mRNAs. Short-interfering RNAs have fewer targets and may
produce more specific gene silencing (Okamura and Lai, 2008).
The desired on-target effects of siRNAs are caused through perfect
base pairing to the target sequence. In addition, the seed-region of
the siRNA antisense (guide) strand can bind SCRs in the 30 UTR of
mRNA molecules that show only partial complementarity, leading
to direct seed-dependent effects.
There is considerable interest in exploiting RNAi using
exogenous siRNAs for therapeutic targeting of disease-specific
genes that are essential for survival of the diseased cells (Phalon
et al, 2010). Suitable candidates include genes encoded by cancer-
associated viruses, as these are not present in uninfected normal
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cells. An important example is high-risk human papillomavirus
(HR-HPV), a necessary cause of cervical carcinoma (Walboomers
et al, 1999), as maintenance of HPV oncogene expression
is essential for the survival of HPV-positive cervical cancer cells
in vitro (Magaldi et al, 2012).
For RNAi to be therapeutically successful, siRNAs need to be
developed and systematically assessed, ensuring they have minimal
harmful, unintended ‘off-target’ effects (OTEs) (Birmingham et al,
2007). For some siRNAs, a 20-O methyl ribosyl modification at
nucleotide position 2 on the antisense strand can provide a 66%
reduction in seed-dependent OTEs (Jackson et al, 2006) and a
proportionate reduction in seed-independent OTEs that result in a
host interferon response (Jackson et al, 2006; Judge and
MacLachlan, 2008). Introducing DNA into the seed region has
also had some success in diminishing OTEs, including when
targeting HPV16 oncogenes, but often at the expense of reducing
silencing activity (Ui-Tei et al, 2008; Yamato et al, 2011).
When designing individual siRNAs for therapeutic use, it is
important to minimise the possibility of OTEs in cells that do not
express the target gene. The approach most commonly used to
assess transcriptional OTEs in such cells is to predict computa-
tionally the numbers of SCR-containing mRNAs that are distinct
from the target gene (Anderson et al, 2008). It is generally assumed
that the higher the number of such predicted OTEs, the greater the
size of the OTE signature and the more likely a detrimental
phenotypic effect will be induced (Anderson et al, 2008; Vaishnaw
et al, 2010). In the present study, we used siRNAs against the major
HPV16 oncogene E7 as a model system to answer two critical
questions. First, do predicted OTEs correlate with actual OTEs?
Second, does the cell type studied have an effect on the actual OTEs
observed? We compared the numbers of computationally predicted
OTEs for four different siRNAs designed to target HPV16 E7 with
the actual OTEs observed following the treatment of HPV-negative
keratinoctyes (squamous epithelial cells). Such cells, in which the
target gene was entirely absent, provided a particularly useful
system for detailed study of the phenotypic and transcriptional
OTEs that would occur in ‘bystander’ non HPV-infected
keratinocytes adjacent to cervical carcinoma cells. We focussed
on siRNAs with the 20-O methyl ribosyl modification, as this is
most likely to be included in future therapeutic siRNAs (Vaishnaw
et al, 2010). Our work has identified significant limitations in
current OTE prediction algorithms, indicating a continuing
requirement for new approaches to OTE identification.
MATERIALS AND METHODS
Cell culture. The squamous epithelial cell lines used were CaSki,
derived from an HPV16-positive human cervical squamous cell
carcinoma (Pattillo et al, 1977), and HaCaT, an immortalised
HPV-negative epidermal (skin) cell line (Boukamp et al, 1988).
The cells were authenticated by short tandem repeat profiling by
the American Type Culture Collection, Manassas, VA, USA.
Primary cultures of normal cervical keratinocytes (NCx) were
obtained from hysterectomy specimens removed for non-neoplas-
tic disease unrelated to the cervix. The NCx cells were HPV
negative by nested PCR and reverse-line blot hybridisation
(Muralidhar et al, 2007). Cell culture and determination of growth
rates were performed as described (Pett et al, 2004; Herdman et al,
2006). Briefly, cells were stained with 0.4% trypan blue (Life
Technologies Inc., Grand Island, NY, USA) and viable cells
counted using a Countess automated cell counter (Life Technol-
ogies Inc.).
siRNA design. Seven siRNAs targeting the HPV16 oncogene E7
were chosen for initial testing. These represented four previously
published siRNAs, E7-Tang (Tang et al, 2006), E7-Jiang (Jiang
and Milner, 2002), E7–573 (Yamato et al, 2008) and E7–752
(Yamato et al, 2008), plus three novel siRNAs designed using
Dharmacon siDESIGN centre (Thermo Scientific, Waltham,
MA, USA). All siRNAs were manufactured by Dharmacon
(Birmingham et al, 2007) (Thermo Scientific), and all contained
the 20-O-methyl ribosyl modification at position 2 on the antisense
strand (Jackson et al, 2006). Of the novel siRNAs, E7–653 and
E7–141 were selected as they had the highest thermodynamic score
and were thus predicted to give the greatest depletion of E7.
E7–127 was chosen as it had the highest thermodynamic score of
the siRNAs that were classed as having ‘low-seed frequency’
(Table 1). Predicted OTEs were determined according to criteria
used by Dharmacon – namely the number of mRNA transcripts in
the whole transcriptome containing an SCR in the 30 UTR that
corresponded to 50 2–7 nt on the siRNA antisense strand. Such
SCRs were identified by searching a database of 30 UTRs obtained
from Sylarray (Bartonicek and Enright, 2010), on the basis of
Ensembl v57 (http://www.ensembl.org/index.html).
siRNA transfection. Cells were cultured in six-well plates, with
CaSki and HaCaT seeded at 1.6 105 cells/well and NCx at 1.9
105 cells/well. Cells were transfected at 30–40% confluency,
following removal of fibroblast feeder cells using 1 phosphate-
buffered saline (1PBS) in the case of NCx. In parallel with each
E7 siRNA experiment, cyclophilin B depletion was performed
using cyclophilin B siRNA (Thermo Scientific), as a transfection
efficiency indicator. Further transfection efficiency analysis was
carried out using a fluorescently labelled siRNA (siGLO green
transfection indicator, Thermo Scientific). All transfections used
lipofectamine RNAiMAX (Invitrogen, Paisley, UK) at 9.6 ml per
well. The final siRNA concentrations used were the lowest that
provided highest transfection efficiency: these were 37 nM unless
stated otherwise. For NCx, feeder cells were added back 12 h after
transfection. Medium was replaced with standard medium at 24 h
post-transfection and replaced every 24 h thereafter, until cells
were harvested. We also used a pool of non-targeting control
siRNAs (ON-TARGET plus non-targeting, Thermo Scientific), at
concentrations identical to those of the test E7-targeting siRNAs.
Table 1. Initial analysis of siRNAs targeting HPV16 E7
siRNA source Name siRNA sense (passenger) strand sequence No. 30 UTR hitsa þ /þ max hit (nt)b Thermodynamic scorec
Tang (19) E7-Tang 50-GCACACACGUAGACAUUCG-30 4255 15 65
Dharmacon E7–127 50-GGACAAGCAGAACCGGACA-30 846 14 73
Dharmacon E7–141 50-GGACAGAGCCCAUUACAAU-30 4501 15 88
Dharmacon E7–653 50-GCUCAGAGGAGGAGGAUGA-30 4640 18 95
Abbreviations: HPV¼human papillomavirus; siRNAs¼ short-interfering RNAs.
aNumber of predicted OTEs.
bHighest number of consecutive nucleotide matches between the siRNA and the human genome.
cThermodynamic score showing the depletion potential of the siRNA, on the basis of several parameters (7).
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RNA extraction and quantitative reverse transcription PCR
(qRT-PCR). RNA was harvested using 1ml of TRIzol (Life
Technologies) per well, after feeder cell removal in the case of
NCx. RNA quality was assessed using the Agilent Bioanalyzer 6000
(Agilent, Stockport, UK) and the RNA stored at  801C until used.
Levels of RNA depletion were measured by qRT-PCR. QuantiTect
reverse transcription kit (Qiagen, Crawley, UK) was used for
cDNA synthesis, using polyT primers alone (Qiagen). Quantitative
PCR was performed using SYBR Green JumpStart Taq ReadyMix
(Sigma-Aldrich, Dorset, UK), with primers (Sigma-Aldrich, unless
specified) listed in Supplementary Table S1. Expression levels were
normalised against the mean of three house-keeping genes (ACTB,
GAPDH and TBP) (Herdman et al, 2006). Quantification of miR-
137 and miR-302f levels was performed using TaqMan qRT-PCR
(Applied Biosystems, Warrington, UK), as described (Muralidhar
et al, 2007).
Western immunoblotting. Cells were harvested with RIPA buffer
(Sigma-Aldrich) containing protease inhibitor (Roche, Basel,
Switzerland), following the removal of feeder cells in the case of
NCx. Extracts were stored in 20% glycerol at  801C. Total-
protein concentration was determined using BCA (bicinchoninic
acid) Protein Assay Kit (Thermo Scientific). Seventy micrograms of
total protein was run on a 12% pre-cast NuPage polyacrylamide
gel (Invitrogen), blotted and analysed by hybridisation of
antibodies against HPV16 E7 (ED17, Santa Cruz Biotechnology,
CA, USA) or HPV16 E6 (1E–6F4, Euromedex, Souffelweyersheim,
France). Detection was carried out using ECL-Plus Western
Blotting Detection System (GE Healthcare, Amersham, UK).
Protein levels were normalised to those of b-tubulin (ab6046,
Abcam, Cambridge, UK).
Microarray expression profiling. Total RNA (1 mg) was labelled
and hybridised as described (Winder et al, 2011). The bead-level
data (raw text files containing background-corrected foreground
intensities) obtained from BeadScan software were read using the
Bioconductor beadarray package (version 2.2.0) (Dunning et al,
2008). The data were converted to bead-summary data using
summarise function and the default logGreenChannelTransform
transformation (Dunning et al, 2007), after detecting and removing
the spatial artefacts using the BeadArray Subversion of Harshlight
(BASH) tool, as part of the Bioconductor beadarray package
(Barbosa-Morais et al, 2010). The mean and s.d. of the remaining
beads were calculated. The log2-transformed data were then
quantile normalised. The probes were filtered on the basis of the
expression-detection score (Po0.05) and duplicate probes further
removed on the basis of the interquartile range filtering. We used
the Bioconductor annotation file illuminaHumanv4.db (Barbosa-
Morais et al, 2010) to retrieve Entrez Gene identifiers and gene
symbols for the probes. The raw (.txt) and normalised intensities
files are available at ArrayExpress (Accession: E-MTAB-967).
To detect differentially expressed genes, the normalised
expression values were analysed using linear models with limma
(Smyth, 2004). Significance of differential expression was tested by
an empirical Bayes moderated t-test and adjusted for multiple-
testing using Benjamini and Hochberg’s method (Benjamini et al,
2001). For each siRNA, we obtained lists of differentially expressed
probes with more than two-fold change (log2 fold-change of 1) in
either direction, and an adjusted P-value ofo0.05, compared with
untreated cells. The overlap between genes differentially expressed
in NCx and HaCaT cells was plotted using the Bioconductor
venndiagram package (http://faculty.ucr.edu/Btgirke/Documents/
R_BioCond/My_R_Scripts/vennDia.R).
Pathway enrichment analysis. The lists of up- and downregulated
genes were used for Gene Ontology (GO) and Kyoto Encyclopae-
dia of Genes and Genomes (KEGG) pathway analysis, performed
using the conditional hyperGTest function from the Bioconductor
GOstats package (Falcon and Gentleman, 2007). To obtain the
gene universe, we removed probes without Entrez Gene identifiers.
The lists of differentially expressed genes were evaluated for the
enrichment of GO ‘Biological Process’ terms and KEGG pathways
using mappings defined in the Bioconductor illuminaHumanv4.db
annotation library (Barbosa-Morais et al, 2010). Categories with
adjusted P-values o0.05 (Benjamini et al, 2001) were considered
significant.
Gene-set enrichment analysis and functional maps. We also
analysed genelists using gene-set enrichment analysis (GSEA) to
identify statistically over-represented groups of genes on the
basis of the expression data (Subramanian et al, 2005). The gene
sets used (http://baderlab.org/GeneSetDB_02?action=AttachFile&
do=view&target=GO_K_NCI_BIOC_PF_Hs_eg.GMT) were derived
from: GO (Biological Process, Molecular Function and Cellular
Component), NCI pathways, KEGG pathways, Reactome and
PFAM protein domain families. Enriched gene sets were graphically
organised into a network using the Cytoscape (Shannon et al, 2003)
plug-in Enrichment Map (Merico et al, 2010), where each gene set
was represented as a node and edges represented overlap between
sets. Node size was proportional to the total number of genes
belonging to the corresponding gene set, while edge thickness
was proportional to the overlap score. We used enriched gene
sets with false-discovery rate q-value o5% to build the enrichment
map.
Sylamer algorithm. Sylamer assesses for enrichment and/or
depletion of nucleotide words of specific length, complementary
to elements of the seed region of miRNAs/siRNAs, in the 30 UTRs
of genes within ranked lists (van Dongen et al, 2008). Significance
is calculated using hypergeometric statistics. We derived a single-
summed significance score for each seed-dependent OTE, as
described previously for miRNA effects (Palmer et al, 2010). This
score was produced by combining Sylamer results for the set of the
core 2–7 nt hexamer, the two heptamers and the single octamer
particular to each enriched SCR (complementary to siRNA 1–8 nt).
The resulting scores fitted an extreme value distribution, allowing
P-values to be assigned, with values o0.01 being deemed
significant (Palmer et al, 2010). We also used a simple w2
contingency test to confirm the significance of any identified SCR
enrichment in downregulated genes for each siRNA.
RESULTS
siRNA potency and predicted OTEs. For each of the seven
siRNAs, we first determined their potency, defined as the ability to
deplete target HPV16 E7 mRNA and protein in CaSki cells. As E7
is co-transcribed with E6 in polycistronic transcripts (Smotkin and
Wettstein, 1986), we measured depletion of both E7 and E6 at the
RNA and protein level, using qRT-PCR and western blotting,
respectively. We observed minimal fluctuation in transfection
efficiency across control experiments, with mean cyclophilin B
depletion of 97% (Supplementary Figure S1A) and mean siGLO
transfection of 97% (Supplementary Figure S1B).
Of the four previously published siRNAs (E7-Tang, E7-Jiang,
E7–573 and E7–752), only E7-Tang had a potency of 470%
(Figure 1A). All three of the novel E7-targeting siRNAs (E7–653,
E7–141 and E7–127) were highly potent at depleting E7 and E6
RNA and protein, particularly at 48 h, which was therefore chosen
as the time point to assess OTEs (Figure 1B). On the basis of the
potency data, OTE analysis was only performed on the three novel
siRNAs and E7-Tang.
By searching for SCRs in 30 UTRs, we determined that all the
top three, most potent siRNAs (E7–141, E7-Tang and E7–653),
had a similar number of predicted OTEs. In contrast, E7–127 had
over five-fold fewer predicted OTEs (Table 1). If the assumptions
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about the prediction algorithm were correct, it followed that E7–
127 would induce the fewest significant OTEs in vitro.
Phenotypic OTEs. We first measured growth inhibitory effects of
the four selected siRNAs over a 6-day period, following the
transfection of HaCaT cells. As HaCaT is an HPV-negative cell
line, any observed phenotypic changes were due to siRNA OTEs.
We were unable to use normal cervical keratinocytes (NCx) for this
purpose, as growth of NCx cells is sensitive to a range of factors,
including confluency and the extent of fibroblast feeder cell
support, making direct comparisons of growth rate difficult. In
contrast, HaCaT cells do not require feeder cell support and
provide a straightforward system for quantifying cell growth.
Although the most potent siRNA, E7–141, had no effect on
growth, each of the other three siRNAs caused growth inhibition
(up to 28% compared with control-treated cells) (Figure 2). These
effects were not associated with differences in numbers of predicted
OTEs, as E7–141 had the second highest number of predicted
OTEs (Table 1). We confirmed that none of the siRNAs contained
50 UGGC motifs, which can induce toxic cellular effects (Fedorov
et al, 2006).
In view of the unpredicted effects on cell growth, we next
undertook a detailed analysis of the transcriptional OTEs of all four
siRNAs. We used a microarray approach to quantify the changes in
the global transcriptome of HPV-negative keratinocytes, studying
both primary cultures of NCx and HaCaT (skin) cells, with all
experiments performed in biological triplicate. In these experi-
ments, transfection efficiency was 87.1–91.8% for NCx and 90.7–
93.7% for HaCaT.
Actual vs predicted numbers of transcriptional OTEs. We
determined actual transcriptional OTEs by comparing gene
expression profiles in siRNA-treated cells vs untreated controls,
and identifying differentially expressed transcripts. To assess any
non-specific OTEs, we looked for genes that were significantly
differentially expressed (upregulated or downregulated), following
treatment with all of the four siRNAs (Figure 3A). There were
no such genes in HaCaT and only one gene in NCx (AGR2). We
concluded that the transfection reagent and nonspecific siRNA
effects did not cause any significant OTEs and therefore did not
interfere with our downstream analysis.
Actual seed-dependent OTEs were defined as the number of
downregulated transcripts with a significant two-fold change
(log2FCo¼  1 and adjPvalo0.05) that also contained an SCR
(corresponding to 2–7 nt on the 50 siRNA antisense strand) in their
30 UTR. Across all the eight experiments (four siRNAs, each in two
cell lines), there was no correlation between the numbers of
predicted and actual seed-dependent transcriptional OTEs (P-
value¼ 0.76) (Figure 3B). Indeed, the two siRNAs with the largest
numbers of predicted OTEs (E7–141 and E7–653) caused down-
regulation of approximately the same number of genes as E7–127
(Figure 3B, Table 2), which had five-fold fewer predicted OTEs
(Table 1).
The siRNAs were categorised into groups with high- and low-
predicted SCR frequency, according to the previously used criteria
(Anderson et al, 2008). By this process, there were three siRNAs
with ‘high’ numbers of predicted SCRs (44000) and one with ‘low’
numbers (o1000). There was no significant difference in actual
OTEs between the two groups (P-value 0.65: Figure 3C).
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Consistent with previous reports (Grimson et al, 2007;
Hammell et al, 2008; Selbach et al, 2008), we observed that
1.15% or less of mRNAs that contained an siRNA SCR in their 30
UTR were significantly downregulated (range 0–1.15%). Moreover,
for each analysis, the actual seed-dependent OTEs represented on
average only 20.5% of all differentially-expressed genes (range
0.0–57.9%) (Table 2, Figure 4). Using the w2–test, we found
significant enrichment in downregulated genes (Po0.01) of SCRs
for E7–127 and E7-Tang, in both HaCaT and NCx (Supplementary
Table S2A).
Sylamer analysis of seed-dependent OTEs. We used Sylamer to
test for enrichment and/or depletion of all possible 6, 7 and 8-mer
words in cells treated with each of the four E7-targetting siRNAs,
compared with untreated cells. Two of the siRNAs, E7–127 and
E7-Tang, were found to induce significant actual siRNA seed-
dependent OTEs. These were seen in both HaCaT and NCx
(Figure 5A). The seed-dependent OTEs of E7-Tang were more
highly significant than those of E7–127 (Supplementary Table
S2B). Interestingly, we observed that E7-Tang shared 3–8 nt of its
antisense strand with the seed region (2–7 nt) of the endogenous
miRNA miR-1, resulting in significant downregulation of
mRNAs containing miR-1 SCRs. In contrast, none of the other
siRNAs showed a match for endogenous miRNA seeds. Non-
targeting control siRNA did not induce significant seed-dependent
OTEs (Supplementary Figure S2A).
We also identified that E7–653 caused a sequence-dependent
OTE in NCx (but not in HaCaT) that was not due to the E7–653
seed sequence. The OTE was due to mRNAs in which the 6-mer
nucleotide sequence ‘AGCAAT’ was enriched in the 30 UTR (P-
value 1e 11.3) (Figure 5B). This sequence was complementary to
3–8 nt of the seed region of miR-137 and miR-302f, but not the 2–
7 nt core seed region of these miRNAs. w2 assessment showed no
significant enrichment of the 2–7 nt SCR of these miRNAs in E7–
653-treated HaCaT and NCx (Supplementary Table S2A). More-
over, using Taqman qRT-PCR, we found no elevation in levels
of either miRNA following E7–653 transfection of NCx or HaCaT
(data not shown). Interestingly, E7–653 transfection of NCx
(but not HaCaT) also produced significant enrichment in
downregulated genes of the longer 8-mer SCR sequence 50-CAGC
AATA-30 (P-value 1e 6.1), and both the constituent 7-mers
50-CAGCAAT-30 (P-value 1e 10.4) and 50-AGCAATA-30
(P-value 1e 8.4), each of which contained the 50-AGCAAT-30
6-mer (Figure 5B).
Enrichment of endogenous miRNA SCRs. As siRNA transfec-
tion can upregulate endogenous miRNA targets (Jackson and
Linsley, 2010), we determined the frequency of the 2–7 nt SCR
for a set of 345 conserved human miRNAs in mRNAs upregulated
following treatment with each siRNA, compared with the
frequency in non-upregulated genes. On average, 22.5% of
upregulated genes contained one or more miRNA SCR, which
was comparable to the frequency in the non-upregulated genes
(Supplementary Table S3). In addition, Sylamer assessment of all
possible 6-, 7- or 8-mer words showed no significant enrichment of
endogenous miRNA SCRs in upregulated genes for any of the four
siRNAs in either HaCaT or NCx (Figure 5A). Thus, there was no
general enrichment of miRNA SCRs in genes upregulated
following siRNA treatment.
Pathway analysis of OTEs. To determine whether there was an
association between the numbers of OTEs induced and significance
at a pathway level, we performed pathway analysis of differentially
Table 2. Summary of actual transcriptional OTEs observed
siRNA (No.
30 UTR hits)
Cell
line
Total no. of
differentially expressed
transcripts
No. of
downregulated
transcripts
No. of downregulated
transcripts with SCR (%)
No. of
upregulated
transcripts
No. of upregulated
transcripts with SCR
(%)
E7–127 (846) HaCaT 23 7 4 (17.4) 16 0
NCx 83 30 6 (7.2) 53 0
E7-Tang
(4255)
HaCaT 19 16 11 (57.9) 3 0
NCx 121 77 49 (40.5) 44 9 (7.4)
E7–141
(4501)
HaCaT 3 3 0 0 0
NCx 22 11 6 (27.3) 11 2 (9.1)
E7–653
(4640)
HaCaT 0 0 0 0 0
NCx 30 12 4 (13.3) 18 6 (20)
Abbreviations: OTEs¼off-target effects; SCR¼ seed-complementary region; siRNAs¼ short-interfering RNAs.
Probes were considered differentially expressed if their log2FC was X1 or p 1, with an adjusted P-value o0.05.
0
10
20
30
40
50
60
70
11
42
2
2
7
6
1
11
9
11
24
6
2
22
6
5
4
8
49
2
26
N_E7_127 N_E7_141 N_E7_653 N_E7_Tang
Pe
rc
en
ta
ge
 o
f a
ll d
iff
er
en
tia
lly
 e
xp
re
ss
ed
 g
en
es
Upregulated with seed
Upregulated with no 3′UTR annotation
Upregulated with no seed
Downregulated with seed
Downregulated with no 3′UTR annotation
Downregulated with no seed
Figure 4. Features of the observed transcriptional OTEs in NCx cells.
The bars depict categories of mRNA transcripts differentially expressed
following siRNA treatment. For each pair, the left-hand bar depicts the
upregulated genes and the right hand bar depicts the downregulated
genes.
Predicted vs actual siRNA off-target effects BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2012.564 455
0 5000 10 000 15 000
−30
−20
−10
0
10
20
30
−30
−20
−10
0
10
20
30
0 5000 10 000 15 0000 5000 10 000 15 000
Lo
g1
0(e
nri
ch
me
nt 
P−
va
lu
e)
Lo
g1
0(e
nri
ch
me
nt 
P−
va
lu
e)
Lo
g1
0(e
nri
ch
me
nt 
P−
va
lu
e)
Lo
g1
0(e
nri
ch
me
nt 
P−
va
lu
e)
Lo
g1
0(e
nri
ch
me
nt 
P−
va
lu
e)
Lo
g1
0(e
nri
ch
me
nt 
P−
va
lu
e)
Lo
g1
0(e
nri
ch
me
nt 
P−
va
lu
e)
Lo
g1
0(e
nri
ch
me
nt 
P−
va
lu
e)
E7_141
E7_Tang
E7_653
E7_127
TTACAA (E7_141) TTACAA (E7_141)
ACATTC (E7_Tang(2),miR−1(3))
GACATT (E7_Tang(3))
TGACAT 
ACATTC (E7_Tang(2),miR−1(3))
GACATT (E7_Tang(3))
TGACAT 
AGGATG (E7_653) AGGATG (E7_653)
CCGGAC (E7_127) CCGGAC (E7_127)
HaCaT NCx
0 5000 10 000 15 000
0 5000 10 000 15 000
−10
−5
0
5
10
−10
−5
0
5
10
AGCAAT
0 5000 10 000 15 000
0 5000 10 000 15 000
0 5000 10 000 15 000
CAGCAAT
AGCAATA
CAGCAATA
AGCAATAA
Lo
g1
0(e
nri
ch
me
nt 
P−
va
lu
e)
Lo
g1
0(e
nri
ch
me
nt 
P−
va
lu
e)
Lo
g1
0(e
nri
ch
me
nt 
P−
va
lu
e)
−30
−20
−10
0
10
20
30
−30
−20
−10
0
10
20
30
−30
−20
−10
0
10
20
30
−30
−20
−10
0
10
20
30
−30
−20
−10
0
10
20
30
−30
−20
−10
0
10
20
30
−10
−5
0
5
10
0 5000 10 000 15 000
0 5000 10 000 15 000
0 5000 10 000 15 000
Figure 5. Sylamer analysis of OTEs. Each graph is a Sylamer landscape plot. The x-axis shows the ranked genelist, with genes downregulated
following siRNA transfection to the left and upregulated genes to the right. The y-axis shows log10-transformed and sign-adjusted enrichment P-
values for each SCR word, relative to P-values of all other words. (A) Seed-dependent OTEs of E7–141 (row (i)), E7-Tang (row (ii)), E7–653 (row
(iii)) and E7–127 (row (iv)) in HaCaT (left column) and NCx cells (right column). In all cases, treated cells were compared with their untreated
counterparts. For each siRNA, the 6-mer sequences complementary to the 2–7 nt seed-regions are shown in red. Any other sequences derived
from the region around the 6mers that reached statistical significance are shown in green and blue. In row (ii), E7-Tang(2) and miR-1(3) denote the
sequence complementary to 2–7nt in E7-Tang and 3–8nt in miR-1, whereas E7_Tang(3) denotes the sequence complementary to 3–8 nt in
E7-Tang. (B) Other sequence-dependent OTEs produced by E7–653 in NCx cells. The panels show non-SCR sequences that reached statistical
significance, with 6mer in (i), 7-mers in (ii) and 8-mer in (iii).
BRITISH JOURNAL OF CANCER Predicted vs actual siRNA off-target effects
456 www.bjcancer.com |DOI:10.1038/bjc.2012.564
expressed genes using GO, KEGG and GSEA pathway analysis.
We applied strict criteria in this exercise. We required pathways
to be present in at least two of the three analyses to be considered
enriched and used cut-offs of adjusted (rather than unadjusted)
P-valueso0.05 for GO and KEGG and false discovery rateo0.05
for GSEA. Detailed results are given in Supplementary Tables
S4–S23.
For E7–141, no pathway was enriched in more than one analysis
in either cell line, for either the up- or downregulated genes.
Transcripts downregulated by E7-Tang were linked to reduced
DNA replication, through several pathways (Figure 6A). In
addition, in NCx cells, transcripts that were downregulated by
E7-Tang and contained the corresponding SCR showed enrich-
ment for the term ‘regulation of actin cytoskeleton’. As miR-1 is
functionally linked to actin cytoskeleton organisation (Jiang et al,
2010), the latter observation suggested that an siRNA containing
an endogenous miRNA seed region was capable of acting similarly
to the endogenous miRNA.
In both NCx and HaCaT, E7–127 and E7–653 induced
significant upregulation of genes related to innate immune
responses (Figure 6B and C). E7–127 also showed enrichment for
cell cycle pathways, such as DNA replication and cell division
(Figure 6B), in downregulated genes. Such genes were not enriched
in the SCR-containing downregulated genes, suggesting that the
effect was more likely to be because of the upregulation of innate
immune response genes seen following E7–127 treatment
(Olejniczak et al, 2011). Although GSEA demonstrated upregula-
tion of immune response genes in NCx (but not HaCat) following
treatment with non-targeting control siRNA (Supplementary Figure
S2B), no significant pathways were identified by GO or KEGG.
Comparison of OTEs in NCx vs HaCaT. In view of the different
sequence-dependent OTEs induced by E7–653 in NCx and HaCaT,
we compared all the transcriptional OTEs induced by the four
siRNAs in the two cell types. Although all the significant seed-
dependent and immune-related OTEs that we observed were seen
in both NCx and HaCaT, there was little overlap in the actual
transcripts that showed differential expression in the two cell types
(Supplementary Figure S3A). Of the total number of differentially
expressed transcripts for each siRNA, the percentage that was
differentially expressed in both NCx and HaCaT was only 0–5.9%
(dependent on the stringency of the cut-off used) (Supplementary
Figure S3A and B). These low values were not associated with
major differences in the baseline transcriptional profiles of NCx
and HaCaT, as only 8.6% of expressed genes showed significant
differential expression between untreated NCx and HaCaT cells
(Supplementary Figure S4).
DISCUSSION
Current computational algorithms predict siRNA-induced OTEs
by calculating the number of transcripts containing a 30 SCR
corresponding to the siRNA seed region. It is generally assumed
that siRNAs with a greater number of predicted ‘hits’ will produce
a greater number of actual transcriptional OTEs and hence a more
deleterious phenotype (Anderson et al, 2008). Because of this,
current pipelines for therapeutic siRNA development exclude
siRNAs with high number of predicted OTEs wherever possible
(Vaishnaw et al, 2010). Our data indicate that the underlying
assumption is flawed, as we found no correlation between the
numbers of predicted and actual seed-dependent OTEs for
potential therapeutic siRNAs targeting HPV16-E7.
Review of published literature provides evidence to support our
findings. It was previously shown that there was a positive
correlation between the number of predicted OTEs and the
number of actual OTEs in siRNAs classed as having ‘low’ (o350)
and ‘medium’ (B2500–2800) numbers of predicted SCR hits
(Anderson et al, 2008). However, there was no clear difference in
actual OTEs between siRNAs classed as having ‘low’ and ‘high’
(43800) numbers of predicted OTE hits (Anderson et al, 2008).
Indeed, in the present study, we observed that the siRNAs with
high numbers of SCRs (E7-Tang, E7–141 & E7–653) had no more
actual seed-dependent OTEs than the siRNA with low numbers of
SCRs (E7–127).
Our data also indicated that the consequences of the OTEs
induced by therapeutic siRNAs are not related to the number of
actual OTEs but to the nature of the genes affected. While two of
the HPV16 E7 siRNAs tested (E7–127 and E7–141) induced
similar numbers of actual OTEs, only E7–127 significantly
modulated cellular pathways and induced significant seed-
dependent OTEs on Sylamer analysis. There was an association
between phenotypic OTEs in vitro and the presence of significant
transcriptional OTEs, as the three siRNAs that reduced the growth
of HaCaT cells (E7-Tang, E7–653 and E7–127) all produced
significant transcriptional OTEs that consistently affected key
cellular pathways. In contrast, E7–141 did not induce significant
transcriptional OTEs and did not affect cell phenotype. Differences
in the induction of significant transcriptional OTEs were not
predicted by current bioinformatic algorithms, nor by the total
number of OTEs induced. Instead, pathway analysis was required
for them to be identified.
It is interesting that the two siRNAs with significant seed-
dependent OTEs on Sylamer analysis (E7–127 and E7-Tang) had
the lowest number of predicted OTEs. These findings support the
notion that a general negative correlation may exist between the
number of available SCR-containing genes (i.e., predicted OTEs)
and actual OTEs, as a greater range of mRNA targets bound by an
siRNA may reduce the capacity of that siRNA to deplete levels of
individual mRNAs significantly (Arvey et al, 2010). This view is
consistent with the evidence that pooling siRNAs reduces the
number of significant actual OTEs, despite increasing the number
of predicted OTEs (Kittler et al, 2007). Reduced siRNA
concentration is unlikely to be the only explanation for such an
effect, as lowering the concentration of one siRNA in a pool did
not reduce the number of actual OTEs (Kittler et al, 2007). In
contrast, our data indicated that large numbers of predicted OTEs
do not necessarily reduce siRNA potency (Arvey et al, 2010). The
potency of the four siRNAs tested corresponded more closely to
their thermodynamic score (Birmingham et al, 2007) than to the
numbers of predicted OTEs.
Of the actual transcriptional OTEs induced by the four siRNAs,
on average only 20.5% were due to direct seed-dependent OTEs. In
view of this, we tested for other types of OTE computationally
(Supplementary Figure S5). We looked for evidence of modulation
of endogenous RNAi pathways, leading to upregulation of targets
of endogenous miRNAs. There was no general enrichment of
miRNA SCRs in upregulated genes compared with non-upregu-
lated genes, and no SCRs were enriched on Sylamer analysis,
indicating that endogenous miRNA imbalances did not induce
significant shifts in overall mRNA profiles. However, Sylamer may
have underestimated miRNA effects. The presence of a minimal
6-mer seed match may be insufficient to detect miRNA targets, as
miRNA regulation is influenced by additional targeting parameters
and also depends on the expression levels of miRNAs in the system
studied (Bartel, 2009).
We did observe evidence of seed-independent OTEs, which
are thought to be caused by siRNAs binding intracellular receptors
(Jackson and Linsley, 2010). Two of the siRNAs tested, E7–127
and E7–653, stimulated innate immune pathways in both NCx
and HaCaT. Interestingly, E7–127 had the lowest number of
predicted OTEs, which may have resulted in the highest amount
of unbound siRNAs capable of stimulating host dsRNA receptors,
such as RIG-I-like and NOD-like receptors (Sioud, 2010).
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However, intracellular abundance would not explain the effects of
E7–653, which had as many predicted OTEs as E7–141 and E7-
Tang. E7–653 may instead have shown greater sequence-
dependent binding of innate immune receptors (Sioud, 2010).
In addition, our data suggested that there were indirect
(downstream) OTEs that resulted from the other types of OTE.
Such OTEs affected important cancer-associated pathways,
with the enrichment for cell cycle regulation genes among
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the mRNAs that were significantly downregulated following E7–
127 treatment. These effects were likely to be downstream of E7–
127-induced stimulation of innate immune pathways, as there was
no enrichment for cell cycle pathway genes in the significantly
downregulated SCR-containing mRNAs.
For E7–653, the indirect effects were cell-specific, being
observed in NCx but not HaCaT. These OTEs were because of
the sequences contained within the 8-mer 50-CAGCAATA-30,
which were enriched in the 30 UTRs of mRNAs downregulated by
E7–653 in NCx. Interestingly, the 8-mer sequence was previously
detected as a conserved regulatory motif in mammalian genomes
(Xie et al, 2005). It does not correspond to any known miRNA
binding site, but is thought to be an AU-rich element (ARE) motif
(Xie et al, 2005). AREs are important in controlling gene
expression through mRNA stability and degradation (Chen and
Shyu, 1995) and can contribute to immune system control
networks (Chen and Shyu, 1995; Schott and Stoecklin, 2010).
E7–653 transfection of NCx may therefore cause mRNA degrada-
tion via this ARE motif. We found no evidence of upregulation in
NCx or HaCaT of RNA-binding proteins, such as HuR, that are
implicated in ARE-mediated effects of siRNAs and miRNAs
(Schott and Stoecklin, 2010) (data not shown). Whether these
observations truly represent ARE-mediated mRNA degradation,
and the basis of the observed cell specificity of the E7–653 effects,
therefore remain uncertain.
An interesting general observation from our study was that for
all siRNAs tested there was relatively little overlap between the
actual transcripts that were differentially expressed in NCx vs
HaCaT cells. Nevertheless, all the significant siRNA-seed-depen-
dent and immune-related OTEs that we observed were seen in
both NCx and HaCaT. These results imply that although
individual siRNAs do not consistently affect specific mRNA
targets, there are still common effects on key cellular pathway(s).
This may be partly due to downregulation of genes at different
points in the pathway(s), potentially reflecting prevailing gene
expression levels in the different cell types. On the other hand,
significant ARE-mediated effects on transcript levels were only
seen in NCx and not HaCaT. The overall differences between
the two cell types may reflect their anatomical site of origin
(cervix vs skin) and/or the immortalised phenotype of HaCaT. In
either case, our data imply that it is advisable to use the most
suitable cell type for in vitro investigations of OTEs of therapeutic
siRNAs. When evaluating OTEs of siRNAs designed to treat
cervical carcinoma, we consider the optimal cells to be HPV-
negative NCx. The absence of the true siRNA target in such cells
precludes any indirect effects of on-target gene depletion, which
may be extensive and confound the identification of OTEs that are
significant and clinically relevant in target-negative cells (Anderson
et al, 2008).
We conclude that algorithms for predicting OTEs of therapeutic
siRNAs on the basis of the numbers of SCR-containing mRNA
targets are of limited value, as they do not predict actual
seed-dependent OTEs accurately. Moreover, the number of actual
OTEs observed does not dictate the significance of OTEs at a
pathway level and does not predict the phenotypic effects. Our data
indicate that the therapeutic siRNAs with high numbers of
predicted OTEs should not necessarily be dismissed, and may
even generate fewer actual seed-dependent and/or seed-indepen-
dent OTEs than those with low numbers of predicted OTEs.
This is exemplified by E7–141, which combined high potency with
no significant OTEs in vitro and is a promising candidate for
therapeutic targeting in cervical neoplasia. We suggest that, when
designing siRNAs for therapeutic use, the potency of the siRNAs
should be tested irrespective of the numbers of predicted OTEs.
The most potent siRNAs should then undergo assessment of OTEs
in vitro, using microarray and phenotypic analyses of the most
relevant primary cell type.
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